Genscript Biotech Corporation provided earnings guidance for the year ended 31 December 2021. For the period, the Group is expected to record a loss of approximately $466.9 million to $518.6 million for the year ended 31 December 2021, as compared to a loss of approximately $281.4 million in 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.02 HKD | +2.42% | +5.56% | -44.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.51% | 2.92B | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- 1548 Stock
- News Genscript Biotech Corporation
- Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021